Related Experiment Videos
Desmoplastic and neurotropic melanoma
Lyndon D Su1, Douglas R Fullen, Lori Lowe
1Department of Pathology, University of Michigan Medical Center, Ann Arbor, Michigan48109-0602, USA. lyndonsu@umich.edu
Cancer
|January 28, 2004
Summary
Sentinel lymph node biopsy (SLNB) effectively detects subclinical metastases in desmoplastic and neurotropic melanoma (DNMM). This procedure aids in guiding early treatment and potentially preventing tumor spread in affected patients.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Desmoplastic and neurotropic melanoma (DNMM) can metastasize to regional lymph nodes and extranodal sites.
- The diagnostic and prognostic value of sentinel lymph node biopsy (SLNB) in DNMM remains unclear.
- This study evaluates the utility of SLNB in managing patients with DNMM.
Purpose of the Study:
- To assess the effectiveness of SLNB in identifying lymph node metastases in DNMM patients.
- To determine if SLNB provides valuable information for treatment decisions in DNMM.
- To evaluate the role of SLNB in preventing tumor spread and recurrence.
Main Methods:
- A retrospective review of 33 patients with DNMM who underwent lymphatic mapping and SLNB over a 5-year period.
- Analysis of clinical and histopathologic data, including tumor characteristics and SLNB results.
- Correlation of SLNB findings with subsequent therapeutic lymphadenectomy outcomes.
Main Results:
- Thirty-three DNMM patients underwent SLNB; mean Breslow depth was 4.0 mm.
- 12% of patients (4/33) without clinical metastasis had positive sentinel lymph nodes.
- No further positive lymph nodes were identified in subsequent lymphadenectomies for these four patients.
Conclusions:
- SLNB is effective in detecting subclinical lymph node metastases in DNMM.
- SLNB provides crucial information for early treatment guidance in DNMM management.
- SLNB, combined with lymphadenectomy for positive nodes, may limit disease spread and recurrence.